Cargando…

miR-9 Enhances the Chemosensitivity of AML Cells to Daunorubicin by Targeting the EIF5A2/MCL-1 Axis

Daunorubicin (Dnr) is at the forefront of acute myeloid leukemia (AML) therapy, but drug resistance poses a major threat to treatment success. MicroRNA (miR)-9 has been shown to have a pivotal role in AML development. However, little is known about the role of miR-9 in Dnr resistance in AML. We expl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yanhui, Lei, Pingchong, Qiao, Hong, Sun, Kai, Lu, Xiling, Bao, Fengchang, Yu, Runhong, Lian, Cheng, Li, Yao, Chen, Wei, Xue, Fei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367593/ https://www.ncbi.nlm.nih.gov/pubmed/30745844 http://dx.doi.org/10.7150/ijbs.29775

Ejemplares similares

MiR-20a-5p functions as a potent tumor suppressor by targeting PPP6C in acute myeloid leukemia
por: Bao, Fengchang, et al.
Publicado: (2021)

Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
por: Raut, Lalit S.
Publicado: (2015)

Musashi-2 Silencing Exerts Potent Activity against Acute Myeloid Leukemia and Enhances Chemosensitivity to Daunorubicin
por: Han, Yixiang, et al.
Publicado: (2015)

Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
por: Gyan, Emmanuel, et al.
Publicado: (2022)

Cellular Metabolomics Profiles Associated With Drug Chemosensitivity in AML
por: Stockard, Bradley, et al.
Publicado: (2021)

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
por: Chen, Evan C, et al.
Publicado: (2018)

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results
por: Cortes, Jorge E., et al.
Publicado: (2018)

IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen
por: Libura, Marta, et al.
Publicado: (2021)

Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice
por: Anstee, Natasha S., et al.
Publicado: (2018)

Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis
por: Zhang, Jingyi, et al.
Publicado: (2022)

Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51
por: Xie, Chengzhi, et al.
Publicado: (2013)

Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial
por: Sierra, Jorge, et al.
Publicado: (2023)

Adipocyte metabolism of the chemotherapy daunorubicin
por: Mittelman, Steven D., et al.
Publicado: (2018)

Honokiol Suppressed Pancreatic Cancer Progression via miR-101/Mcl-1 Axis
por: Wang, Yishuo, et al.
Publicado: (2020)

P1362: FEASIBILITY OF HAEMATOPOIETIC STEM CELL MOBILIZATION AFTER CONSOLIDATION WITH GEMTUZUMAB OZOGAMICIN AND INTERMEDIATE-DOSES ARA-C AND DAUNORUBICIN IN AML
por: Perrone, S., et al.
Publicado: (2022)

Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine
por: Tabe, Yoko, et al.
Publicado: (2018)

A-1210477, a selective MCL-1 inhibitor, overcomes ABT-737 resistance in AML
por: Wang, Qing, et al.
Publicado: (2019)

Increased plasma membrane traffic in daunorubicin resistant P388 leukaemic cells. Effect of daunorubicin and verapamil.
por: Sehested, M., et al.
Publicado: (1987)

eIF4E promotes tumorigenesis and modulates chemosensitivity to cisplatin in esophageal squamous cell carcinoma
por: Liu, Ting, et al.
Publicado: (2016)

Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience
por: LaRochelle, Olivier, et al.
Publicado: (2011)

Liposomal daunorubicin as treatment for Kaposi’s sarcoma
por: Petre, Christin E, et al.
Publicado: (2007)

Interactions of Cisplatin and Daunorubicin at the Chromatin Level
por: Firouzi Niaki, Erfaneh, et al.
Publicado: (2020)

A Novel miRNA Restores the Chemosensitivity of AML Cells Through Targeting FosB
por: Wang, Huiwen, et al.
Publicado: (2020)

Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML
por: O’ Reilly, Eimear, et al.
Publicado: (2018)

A critical role of epigenetic inactivation of miR-9 in EVI1(high) pediatric AML
por: Mittal, Nupur, et al.
Publicado: (2019)

A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial
por: Burnett, A K, et al.
Publicado: (2018)

Protein Kinase C Epsilon Overexpression Is Associated With Poor Patient Outcomes in AML and Promotes Daunorubicin Resistance Through p-Glycoprotein-Mediated Drug Efflux
por: Nicholson, Rachael, et al.
Publicado: (2022)

Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL
por: De Falco, Filomena, et al.
Publicado: (2015)

Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML
por: Ewald, Larissa, et al.
Publicado: (2019)

Applications of daunorubicin-loaded PLGA-PLL-PEG-Tf nanoparticles in hematologic malignancies: an in vitro and in vivo evaluation
por: Bao, Wen, et al.
Publicado: (2019)

Gene expression of hENT1, dCK, CDA, dCMPD and topoisomerase IIα as an indicator of chemotherapy response in AML treated with cytarabine and daunorubicin
por: Kulsoom, Bibi, et al.
Publicado: (2018)

Cryptotanshinone chemosensitivity potentiation by TW-37 in human oral cancer cell lines by targeting STAT3–Mcl-1 signaling
por: Yang, In-Hyoung, et al.
Publicado: (2020)

CircRNA-DOPEY2 enhances the chemosensitivity of esophageal cancer cells by inhibiting CPEB4-mediated Mcl-1 translation
por: Liu, Zhenchuan, et al.
Publicado: (2021)

MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer
por: Wang, Huaqi, et al.
Publicado: (2017)

miR-3656 expression enhances the chemosensitivity of pancreatic cancer to gemcitabine through modulation of the RHOF/EMT axis
por: Yang, Rui-Meng, et al.
Publicado: (2017)

Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis
por: Li, Bin, et al.
Publicado: (2017)

Deoxyelephantopin Induces Apoptosis and Enhances Chemosensitivity of Colon Cancer via miR-205/Bcl2 Axis
por: Ji, Haoyan, et al.
Publicado: (2022)

LncRNA UCA1 promotes tumor metastasis by inducing miR-203/ZEB2 axis in gastric cancer
por: Gong, Pihai, et al.
Publicado: (2018)

Melt electrospinning of daunorubicin hydrochloride-loaded poly (ε-caprolactone) fibrous membrane for tumor therapy
por: Lian, He, et al.
Publicado: (2017)

Correction to: CircRNA-DOPEY2 enhances the chemosensitivity of esophageal cancer cells by inhibiting CPEB4-mediated Mcl-1 translation
por: Liu, Zhenchuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ld0h9jl6r3gffmmftvsciqmimg